What to do if I get spotting or burning after treatment?
What to do if I get spotting or burning after treatment? Mild, short-lived spotting or a warm, sunburn-like sensation can occur after gentle vaginal laser/radiofrequency or superficial injectables, and usually settles with low-friction care. Pause irritants, use a generous lubricant, and monitor for 48–72 hours. However, malodorous discharge, fever, severe pelvic pain, visible blood in urine, or new post-menopausal bleeding need medical assessment. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
What to do if I get spotting or burning after treatment? First, identify what you had and where your symptoms sit. After gentle vaginal radiofrequency/laser, brief spotting and a warm, sunburn-like sensitivity are common for a day or two. After superficial vestibular/vaginal injectables (platelet-rich plasma or polynucleotides), pinpoint bruising, tenderness, or tiny oozes can occur. In genitourinary syndrome of menopause (GSM)—also called vaginal atrophy—the tissue is thinner and drier, so friction from clothing or movement can feel exaggerated and cause dyspareunia or “paper-cut” micro-tears at the entrance. Most mild effects settle with simple, low-friction steps; red-flag features need review.
48–72 hours of “calm care.” Keep cleansing gentle (lukewarm water; a bland emollient as a soap substitute if you need product), pat dry, and wear breathable underwear. Avoid fragranced washes, wipes, bubble bath and tight synthetic kit. If walking or cycling chafes, reduce duration briefly and, before activity, smooth a pea of lubricant directly around the vestibule and the posterior fourchette. For intimacy, wait until tenderness and spotting resolve (often 3–7 days after RF/laser or 3–5 days after superficial injectables), then restart with generous lubricant and shallow, adjustable positions.
Placement often matters more than product. If the burning is entrance-focused, internal-only care misses the hotspot. With creams (e.g., local oestrogen), add a fingertip to the vestibule and posterior fourchette as well as inside; with moisturisers, schedule 2–4 nights weekly; with lubricants, place some externally at the entrance before and during higher-friction moments. Water-based options are versatile and condom-friendly; silicone-based formulas give the longest glide when the vestibule is tender; oil-based products feel rich but can degrade latex condoms and some toys.
How to tell normal settling from a problem. Likely normal: light, short-lived spotting; mild warmth; small bruises where needles entered; transient stinging that fades with lubricant. Concerning: malodorous green/grey discharge (possible bacterial vaginosis), intense itch with thick white discharge (possible thrush), fever, severe pelvic pain, visible blood in urine, or new post-menopausal bleeding. New ulcers, rapidly changing white plaques, or pain that worsens despite gentle care also warrant assessment. If you’re unsure whether your symptoms are due to GSM or another condition, see our overview of clinical conditions we assess and how we stage decisions under treatment steps.
Reduce friction while tissues settle. Use a scheduled vaginal moisturiser (many prefer hyaluronic-acid gels) to support baseline comfort and a generous personal lubricant for higher-movement moments. Re-apply early; sting often reflects under-lubrication, not that you’re doing anything wrong. Change out of sweaty kit promptly and rinse chlorine after swimming. If cycling aggravates the posterior fourchette, adjust saddle/positioning and consider padded shorts; a touch of silicone-based lubricant at the entrance before rides can help.
When you use local therapies. Local vaginal oestrogen (cream, tablet/pessary, or ring) or vaginal DHEA can improve moisture, pH and epithelial maturity over weeks. Early on, a few people notice transient stinging or light spotting; correct placement and patience (2–6 weeks) usually help. If stinging persists beyond the first few uses, review technique (are you targeting the vestibule?) and check for contact irritants or infection. Never continue through red flags.
If you’re on blood thinners. Small bruises/spotting after superficial injectables are more likely. Don’t stop anticoagulants/antiplatelets without medical advice. Instead, time sessions carefully, use meticulous pressure after treatment, and follow aftercare closely; seek help for heavy bleeding, large haematomas, or prolonged oozing.
Document and communicate. Keep a short diary of what you did (product or procedure), where it was placed, and what you felt (sting with urine, micro-tears, timing of spotting). This helps your clinician distinguish normal settling from a treatable issue and fine-tune placement, pacing and product choice at review.
Clinical Context
Who is most likely to notice spotting/burning? People with very dry, fragile epithelium from GSM, entrance-focused soreness, or recent higher-friction activity. Warming/tingling products, perfumes, and high-osmolality lubricants can magnify sting. Precision at the vestibule and switching to minimal-ingredient products reduce setbacks.
Who should pause and seek review? Anyone with malodorous discharge, fever, severe pelvic pain, visible haematuria, or new post-menopausal bleeding. Procedures should be deferred if you have active BV/thrush/UTI or are recovering from pelvic/perineal surgery without clearance. Severe fish allergy generally excludes salmon-derived polynucleotides.
Next steps you can take now. Strip back to lukewarm water and a bland emollient as a soap substitute; schedule a moisturiser 2–4 nights weekly; use a generous, compatible lubricant (silicone-based often gives the longest glide for dyspareunia); and restart intimacy only when settled. Educational only. Results vary. Not a cure.
Evidence-Based Approaches
Patient-friendly basics (UK): The NHS explains symptoms, self-care and when to seek help for vaginal dryness, including irritation clues and practical soothing measures.
Guideline framing: The NICE Menopause Guideline (NG23) recommends information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life; this supports a foundations-first approach and safe escalation.
Prescribing/product detail: Dosing and cautions for local vaginal oestrogens and prasterone (DHEA) are listed in the British National Formulary (BNF), including technique tips that reduce stinging (e.g., vestibule targeting with creams).
Effectiveness benchmarks: Systematic reviews in the Cochrane Library show local vaginal oestrogens improve dryness, soreness, dyspareunia and pH versus placebo across creams, tablets/pessaries and rings—useful context when judging post-procedure improvements.
Pathophysiology detail: Peer-reviewed overviews indexed on PubMed describe GSM biology (thinner epithelium, higher pH, fewer lactobacilli) and clarify why low-friction aftercare plus local therapy often settle burning faster than changing devices alone.